AxoGen, Inc. — News

Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.

seekingalpha.com - 2026-08-03 02:37:45

AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)'s stock price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $41.15, but opened at $38.31. AxoGen shares last traded at $44.5120, with a volume of 317,776 shares trading hands. The medical equipment provider reported

defenseworld.net - 2026-07-30 02:01:44

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-29 14:43:24

AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.

marketbeat.com - 2026-07-29 10:05:26

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

zacks.com - 2026-07-29 09:26:18

/PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a

prnewswire.com - 2026-07-29 07:10:00

ALACHUA, Fla. and TAMPA, Fla.

globenewswire.com - 2026-07-29 07:05:00

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

globenewswire.com - 2026-07-15 07:00:00

ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026.

globenewswire.com - 2026-07-15 07:00:00

AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.

investors.com - 2026-06-05 14:25:58

AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.

marketbeat.com - 2026-05-14 11:07:07

Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

seekingalpha.com - 2026-05-13 18:00:46